Samantha Smythe
Family · Lake City, FLNPI 1902466881
Payments from drug & device makers
Across 205 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Merck$301
- AbbVie$164
- Amgen$163
- Novartis$129
- Mylan Specialty L.p.$127
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,310100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 83 | $1,190 |
| Merck | 17 | $301 |
| AbbVie | 8 | $164 |
| Amgen | 11 | $163 |
| Novartis | 7 | $129 |
| Mylan Specialty L.p. | 6 | $127 |
| Lilly USA, LLC | 7 | $112 |
| Sanofi-aventis U.S. LLC | 6 | $89 |
| Teva Pharmaceuticals USA, Inc. | 5 | $73 |
| Biogen | 5 | $71 |
| Pfizer | 4 | $67 |
| Exact Sciences | 4 | $67 |
| Esperion Therapeutics, Inc. | 4 | $63 |
| Bayer | 4 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| AstraZeneca | 4 | $57 |
| Boston Scientific | 2 | $48 |
| Phathom Pharmaceuticals, Inc. | 2 | $46 |
| Lundbeck LLC | 2 | $44 |
| Inspire Medical Systems, Inc. | 2 | $42 |
| Biohaven Pharmaceuticals, Inc. | 2 | $38 |
| Corcept Therapeutics | 2 | $37 |
| GSK | 2 | $34 |
| Vifor Pharma, Inc. | 1 | $30 |
| Edwards Lifesciences | 1 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
How this compares
$3,310 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 89 | $96,638 |
| JardianceEmpagliflozin | 40 | $42,875 |
| EntrestoSacubitril/Valsartan | 35 | $39,633 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $35,861 |
| OzempicSemaglutide | 25 | $35,768 |
| FarxigaDapagliflozin Propanediol | 24 | $31,703 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $23,806 |
| Repatha SureclickEvolocumab | 23 | $22,148 |
| JanuviaSitagliptin Phosphate | 29 | $16,876 |
| XareltoRivaroxaban | 11 | $15,677 |
| TrulicityDulaglutide | 13 | $15,005 |
| VascepaIcosapent Ethyl | 20 | $13,292 |
| MounjaroTirzepatide | 12 | $12,375 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $12,059 |
| Losartan Potassium | 361 | $3,176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $67 | $96,63889 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $34 | $47,92055 claims |
| Boehringer IngelheimJardiance | $13 | $42,87540 claims |
| NovartisEntresto | $129 | $39,63335 claims |
| Novo NordiskOzempic | $1,190 | $35,76825 claims |
| AstraZenecaFarxiga | $57 | $31,70324 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $112 | $27,38025 claims |
| MerckJanuvia | $301 | $16,87629 claims |
| Johnson & JohnsonXarelto | $15 | $15,67711 claims |
| AbbVieSynthroid | $164 | $72812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Lake City
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.